THERAVANCE BIOPHARMA INC (TBPH) Fundamental Analysis & Valuation

NASDAQ:TBPH • KYG8807B1068

13.665 USD
-0.3 (-2.11%)
At close: Mar 4, 2026
13.7 USD
+0.04 (+0.26%)
After Hours: 3/4/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TBPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Taking everything into account, TBPH scores 4 out of 10 in our fundamental rating. TBPH was compared to 193 industry peers in the Pharmaceuticals industry. The financial health of TBPH is average, but there are quite some concerns on its profitability. TBPH has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

3

1. TBPH Profitability Analysis

1.1 Basic Checks

  • TBPH had negative earnings in the past year.
  • TBPH had a positive operating cash flow in the past year.
  • In the past 5 years TBPH reported 4 times negative net income.
  • In the past 5 years TBPH always reported negative operating cash flow.
TBPH Yearly Net Income VS EBIT VS OCF VS FCFTBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

1.2 Ratios

  • TBPH has a Return On Assets of 7.06%. This is amongst the best in the industry. TBPH outperforms 88.60% of its industry peers.
  • TBPH has a better Return On Equity (12.61%) than 87.05% of its industry peers.
Industry RankSector Rank
ROA 7.06%
ROE 12.61%
ROIC N/A
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TBPH Yearly ROA, ROE, ROICTBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • TBPH's Profit Margin of 36.53% is amongst the best of the industry. TBPH outperforms 96.37% of its industry peers.
  • The Operating Margin and Gross Margin are not available for TBPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 36.53%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TBPH Yearly Profit, Operating, Gross MarginsTBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. TBPH Health Analysis

2.1 Basic Checks

  • TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TBPH has been increased compared to 1 year ago.
  • The number of shares outstanding for TBPH has been reduced compared to 5 years ago.
  • Compared to 1 year ago, TBPH has a worse debt to assets ratio.
TBPH Yearly Shares OutstandingTBPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
TBPH Yearly Total Debt VS Total AssetsTBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 0.02, we must say that TBPH is in the distress zone and has some risk of bankruptcy.
  • TBPH's Altman-Z score of 0.02 is in line compared to the rest of the industry. TBPH outperforms 50.78% of its industry peers.
  • TBPH has a debt to FCF ratio of 0.13. This is a very positive value and a sign of high solvency as it would only need 0.13 years to pay back of all of its debts.
  • TBPH has a Debt to FCF ratio of 0.13. This is amongst the best in the industry. TBPH outperforms 97.41% of its industry peers.
  • TBPH has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
  • TBPH's Debt to Equity ratio of 0.14 is in line compared to the rest of the industry. TBPH outperforms 47.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 0.13
Altman-Z 0.02
ROIC/WACCN/A
WACC9.07%
TBPH Yearly LT Debt VS Equity VS FCFTBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • TBPH has a Current Ratio of 9.48. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
  • TBPH's Current ratio of 9.48 is fine compared to the rest of the industry. TBPH outperforms 79.27% of its industry peers.
  • A Quick Ratio of 9.48 indicates that TBPH has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 9.48, TBPH is doing good in the industry, outperforming 79.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.48
Quick Ratio 9.48
TBPH Yearly Current Assets VS Current LiabilitesTBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. TBPH Growth Analysis

3.1 Past

  • TBPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.53%.
  • Looking at the last year, TBPH shows a very strong growth in Revenue. The Revenue has grown by 27.12%.
  • The Revenue has been decreasing by -2.59% on average over the past years.
EPS 1Y (TTM)-10.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%126.92%
Revenue 1Y (TTM)27.12%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%18.51%

3.2 Future

  • The Earnings Per Share is expected to grow by 19.57% on average over the next years. This is quite good.
  • Based on estimates for the next years, TBPH will show a very strong growth in Revenue. The Revenue will grow by 26.23% on average per year.
EPS Next Y277.49%
EPS Next 2Y69.83%
EPS Next 3Y24.96%
EPS Next 5Y19.57%
Revenue Next Year71.99%
Revenue Next 2Y26.75%
Revenue Next 3Y23.76%
Revenue Next 5Y26.23%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TBPH Yearly Revenue VS EstimatesTBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
TBPH Yearly EPS VS EstimatesTBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

5

4. TBPH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TBPH. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 14.18, the valuation of TBPH can be described as correct.
  • Based on the Price/Forward Earnings ratio, TBPH is valued cheaply inside the industry as 84.97% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 25.11. TBPH is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 14.18
TBPH Price Earnings VS Forward Price EarningsTBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, TBPH is valued cheaper than 98.45% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.84
EV/EBITDA N/A
TBPH Per share dataTBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

  • TBPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as TBPH's earnings are expected to grow with 24.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.83%
EPS Next 3Y24.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TBPH Dividend Analysis

5.1 Amount

  • TBPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TBPH Fundamentals: All Metrics, Ratios and Statistics

THERAVANCE BIOPHARMA INC

NASDAQ:TBPH (3/4/2026, 8:00:01 PM)

After market: 13.7 +0.04 (+0.26%)

13.665

-0.3 (-2.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-02
Earnings (Next)05-06
Inst Owners97.32%
Inst Owner Change2.36%
Ins Owners4.25%
Ins Owner Change-5.89%
Market Cap692.41M
Revenue(TTM)80.33M
Net Income(TTM)29.34M
Analysts81.54
Price Target27.25 (99.41%)
Short Float %9.29%
Short Ratio9.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.59%
Min EPS beat(2)-178.66%
Max EPS beat(2)153.48%
EPS beat(4)1
Avg EPS beat(4)-21.5%
Min EPS beat(4)-178.66%
Max EPS beat(4)153.48%
EPS beat(8)2
Avg EPS beat(8)-16.75%
EPS beat(12)4
Avg EPS beat(12)-14.07%
EPS beat(16)4
Avg EPS beat(16)-30.83%
Revenue beat(2)0
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-1.81%
Max Revenue beat(2)-1.36%
Revenue beat(4)1
Avg Revenue beat(4)0.44%
Min Revenue beat(4)-2.67%
Max Revenue beat(4)7.58%
Revenue beat(8)3
Avg Revenue beat(8)-0.1%
Revenue beat(12)4
Avg Revenue beat(12)-3.78%
Revenue beat(16)6
Avg Revenue beat(16)-3.51%
PT rev (1m)0%
PT rev (3m)28.23%
EPS NQ rev (1m)0.16%
EPS NQ rev (3m)-1.24%
EPS NY rev (1m)0.08%
EPS NY rev (3m)105.42%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)10.2%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)-4.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.18
P/S 8.62
P/FCF 2.84
P/OCF 2.84
P/B 2.98
P/tB 2.98
EV/EBITDA N/A
EPS(TTM)-1.05
EYN/A
EPS(NY)0.96
Fwd EY7.05%
FCF(TTM)4.81
FCFY35.16%
OCF(TTM)4.81
OCFY35.2%
SpS1.59
BVpS4.59
TBVpS4.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 7.06%
ROE 12.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 36.53%
GM N/A
FCFM 303.11%
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 0.13
Debt/EBITDA N/A
Cap/Depr -13.08%
Cap/Sales 0.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 829.74%
Current Ratio 9.48
Quick Ratio 9.48
Altman-Z 0.02
F-Score9
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)53.03%
Cap/Depr(5y)62.83%
Cap/Sales(3y)1.99%
Cap/Sales(5y)4.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%126.92%
EPS Next Y277.49%
EPS Next 2Y69.83%
EPS Next 3Y24.96%
EPS Next 5Y19.57%
Revenue 1Y (TTM)27.12%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%18.51%
Revenue Next Year71.99%
Revenue Next 2Y26.75%
Revenue Next 3Y23.76%
Revenue Next 5Y26.23%
EBIT growth 1Y16.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y259.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y262.26%
OCF growth 3YN/A
OCF growth 5YN/A

THERAVANCE BIOPHARMA INC / TBPH FAQ

What is the fundamental rating for TBPH stock?

ChartMill assigns a fundamental rating of 4 / 10 to TBPH.


What is the valuation status for TBPH stock?

ChartMill assigns a valuation rating of 5 / 10 to THERAVANCE BIOPHARMA INC (TBPH). This can be considered as Fairly Valued.


How profitable is THERAVANCE BIOPHARMA INC (TBPH) stock?

THERAVANCE BIOPHARMA INC (TBPH) has a profitability rating of 3 / 10.


Can you provide the financial health for TBPH stock?

The financial health rating of THERAVANCE BIOPHARMA INC (TBPH) is 6 / 10.


What is the earnings growth outlook for THERAVANCE BIOPHARMA INC?

The Earnings per Share (EPS) of THERAVANCE BIOPHARMA INC (TBPH) is expected to grow by 277.49% in the next year.